<DOC>
	<DOCNO>NCT00862342</DOCNO>
	<brief_summary>Bevacizumab beyond progression proven safe community setting ( BRiTE ) post-marketing study ( BEAT ) , confirm efficacy safety first line regimens chemotherapy . A total 1,953 patient treat BRiTE . At median follow-up 17.5 mo , 1,369 1st PD 839 death . Among patient 1st PD , 65.2 % receive 2nd-line chemotherapy , 34.8 % receive cetuximab , 53.8 % receive BBP . In multivariate analysis , Bevacizumab beyond first progression exposure 2nd-line chemotherapy independently associate increase overall survival ( p &lt; 0.0001 ) . Bevacizumab beyond progression appear associate long overall BRiTE . The investigator plan prospective study prove phenomenon bevacizumab beyond progression .</brief_summary>
	<brief_title>Post-First Progression Use Bevacizumab Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description>Patients treat bevacizumab plus chemotherapy 1st line treatment , 1st progression , patient accrue study bevacizumab plus chemotherapy 2nd line treatment , combine chemotherapy chosen physician 's decision consider previous chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically document colorectal adenocarcinoma Progression firstline bevacizumab contain chemotherapy within 3 month No serious toxicity bevacizumab 1st line treatment Unresectable metastasis Unidimensional measurable lesion ( ) RECIST Age 18 year old ECOG 02 Adequate organ function clinical laboratory exams Other tumor type adenocarcinoma CNS metastases GI bleed Hypersensitivity chemotherapeutic agent Prior use cetuximab target agent bevacizumab Major surgery within 6 week Other serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>